|
Bipolar Disorder
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1.
|
9149325 |
1996 |
|
Bipolar Disorder
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1.
|
9149325 |
1996 |
|
Bipolar Disorder
|
0.350 |
Biomarker
|
disease |
PSYGENET |
We have found evidence of an allelic association between bipolar disorder and a marker at the pancreatic phospholipase A2 gene (PLA2A) in this region (p < or = 0.01).
|
8750360 |
1995 |
|
Bipolar Disorder
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
We have found evidence of an allelic association between bipolar disorder and a marker at the pancreatic phospholipase A2 gene (PLA2A) in this region (p < or = 0.01).
|
8750360 |
1995 |
|
Mood Disorders
|
0.320 |
Biomarker
|
group |
BEFREE |
In the present study, the possible association between the PLA2 gene and unipolar affective disorder was examined on 321 unipolar patients and 604 controls (all personally interviewed), recruited from six countries (Belgium, Bulgaria, Croatia, Germany, Greece, and Italy) participating in the European Collaborative Project on Affective Disorders.
|
14639048 |
2003 |
|
Mood Disorders
|
0.320 |
Biomarker
|
group |
PSYGENET |
These findings suggest that structural variations at the PLA2 gene or the chromosomal region around it may confer susceptibility for unipolar affective disorder.
|
14639048 |
2003 |
|
Mood Disorders
|
0.320 |
Biomarker
|
group |
BEFREE |
The maximum evidence for linkage was given by a polymorphism at the gene encoding secretory phospholipase A2 (PLA2A), a candidate gene for affective disorder.Dawson et al.
|
9149325 |
1996 |
|
Mood Disorders
|
0.320 |
Biomarker
|
group |
PSYGENET |
The maximum evidence for linkage was given by a polymorphism at the gene encoding secretory phospholipase A2 (PLA2A), a candidate gene for affective disorder.Dawson et al.
|
9149325 |
1996 |
|
Drug-induced depressive state
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.
|
20034614 |
2010 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among all the existing isoforms, secretory PLA2 is the major target for inhibitor development, since many studies have proven that this enzyme participates in various inflammatory conditions, such as cancer, Alzheimer and arthritis.
|
30706775 |
2020 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of PLA2R-AB in longitudinal serum samples revealed seropositivity in 44% (59 out of 134) of primary MN cases, 3% (one out of 35) of secondary MN cases, and in 0% of healthy controls.
|
31843984 |
2020 |
|
Idiopathic Membranous Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease.
|
31730818 |
2020 |
|
Idiopathic Membranous Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship between the status of phospholipase A2 receptor and prognosis of idiopathic membranous nephropathy.
|
31226230 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bee Venom Soluble Phospholipase A2 Exerts Neuroprotective Effects in a Lipopolysaccharide-Induced Mouse Model of Alzheimer's Disease <i>via</i> Inhibition of Nuclear Factor-Kappa B.
|
31736738 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first part of this review article focuses on the role of pancreatic-derived PLA2G1B in mediating lipid absorption and discusses how the PLA2G1B-derived metabolic product contributes to cardiometabolic diseases, including obesity, hyperinsulinemia, hyperlipidemia, and atherosclerosis.
|
30003964 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The first part of this review article focuses on the role of pancreatic-derived PLA2G1B in mediating lipid absorption and discusses how the PLA2G1B-derived metabolic product contributes to cardiometabolic diseases, including obesity, hyperinsulinemia, hyperlipidemia, and atherosclerosis.
|
30003964 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several recent studies revealed that phospholipid metabolising enzyme, phospholipase A2 (PLA<sub>2</sub>), is a critical regulator of cancer accelerating pathologies and apoptosis in several types of cancers.
|
29104026 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, recent studies revealing a relationship between PLA2G1B and cancer will also be discussed.
|
30003964 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring calcium ion-dependent effect on the intermolecular interaction between human secreted phospholipase A2 and its peptide inhibitors in coronary artery disease.
|
31536875 |
2019 |
|
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring calcium ion-dependent effect on the intermolecular interaction between human secreted phospholipase A2 and its peptide inhibitors in coronary artery disease.
|
31536875 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While there is an increasing understanding of primary MN with the discovery of antibodies directed against phospholipase A2 receptor (PLA2R Ab) and thrombospondin type 1 domain-containing 7A, circulatory factors causative of inducing MCD and FSGS remain in part elusive.
|
31447217 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discovery in 2009 of the M-type phospholipase A2 receptor (PLA2R) as the primary target in membranous nephropathy (MN) greatly advanced basic and clinical research.
|
31611068 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autoantibodies both to the M-type phospholipase A2 receptor (PLA2R) and to thrombospondin type-1 domain-containing 7A (THSD7A), initially described in adult MN, have now been identified in children and adolescents with MN and serve as a useful diagnostic and monitoring tool in this younger population as well.
|
31811540 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the pathogenesis of MN is still controversial, the detection of autoantibodies against two specific glomerular antigens, phospholipase A2 receptor (PLA<sub>2</sub>R) and thrombospondin type 1 domain containing 7A (THSD7A), together with the beneficial effect of therapies targeting B cells, have highlighted the main role of autoreactive B cells driving this renal disease.
|
31788474 |
2019 |
|
Membranous glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
|
31243451 |
2019 |